A new blood test that looks for circulating tumor cells could significantly improve the diagnosis of prostate cancer and avoid unnecessary biopsies and treatments.
A new blood test could help many people at risk of prostate cancer avoid unnecessary biopsies.
Combining the new test with prostate specific antigen (PSA) results can yield a diagnosis of aggressive prostate cancer that is more than 90% accurate, according to a Journal of Urology study.
This level of accuracy is higher than that of any other biomarker for prostate cancer, says senior and corresponding study author Dr. Yong-Jie Lu, a professor of molecular oncology at the Barts Cancer Institute of Queen Mary University of London in the United Kingdom.
“This could lead to a paradigm shift in the way we diagnose prostate cancer,” he adds.
Circulating tumor cells are cancer cells that have left the original tumor and entered the bloodstream. Once cancer cells are in the bloodstream, they can spread to other parts of the